Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2
Hørsholm, Denmark, January 20, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal The Lancet Microbe published an article about the COVID-19 vaccine candidate ABNCoV2 titled “First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2” co-authored by ExpreS2ion scientists.
Abstract excerpt: “Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2.”
This publication is a result of the close research collaboration in the COUGH-1 trial study group under the Prevent-nCoV consortium as announced in August 2021 and November 2021.
The scientific article reference: Merel J Smit; Adam F Sander; Maud B P A Ariaans; Cyrielle Fougeroux; Constanze Heinzel; Rolf Fendel; Meral Esen; Peter G Kremsner; Rob ter Heine; Heiman F Wertheim; Manja Idorn; Søren Riis Paludan; Alexander P Underwood; Alekxander Binderup; Santseharay Ramirez; Jens Bukh; Max Soegaard; Sayit M Erdogan; Tobias Gustavsson; Stine Clemmensen; Thor G Theander; Ali Salanti; Mette Hamborg; Willem A de Jongh; Matthew B B McCall; Morten A Nielsen; Benjamin G Mordmüller; Robert Dagil; Louise Goksøyr; Thomas M Hulen; Christoph Janitzek; Daniel S Jensen; Sune Justesen; Paul K Khalifé; Andrea Kreidenweiss; Telma Lança; Olivia Lie-Andersen; Karina Teelen; Elena Vidal-Calvo. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. The Lancet Microbe. 2023 - https://doi.org/10.1016/S2666-5247(22)00337-8. The article can also be found via this link, as well as via the Research Publications page of ExpreS2ion’s website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
